Stryker (SYK) Stock Forecast & Price Target

Compare

2,576 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SYK Analyst Ratings

Strong Buy

17 Buy

3 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Stryker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SYK Stock 12 Month Forecast

Average Price Target

$430.32

▲(18.29% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Stryker in the last 3 months. The average price target is $430.32 with a high forecast of $465.00 and a low forecast of $390.00. The average price target represents a 18.29% change from the last price of $363.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"350":"$350","379":"$379","408":"$408","437":"$437","466":"$466"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":465,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$465.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":430.32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$430.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":390,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$390.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[350,379,408,437,466],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,351.47,360.20307692307694,368.93615384615384,377.6692307692308,386.4023076923077,395.1353846153846,403.86846153846153,412.60153846153844,421.3346153846154,430.0676923076923,438.8007692307692,447.5338461538462,456.26692307692304,{"y":465,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,351.47,357.53538461538466,363.60076923076923,369.66615384615386,375.7315384615385,381.79692307692306,387.8623076923077,393.9276923076923,399.99307692307696,406.05846153846153,412.12384615384616,418.1892307692308,424.25461538461536,{"y":430.32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,351.47,354.43384615384616,357.39769230769235,360.3615384615385,363.3253846153846,366.2892307692308,369.25307692307695,372.2169230769231,375.1807692307692,378.1446153846154,381.10846153846154,384.0723076923077,387.03615384615387,{"y":390,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":357.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":388.67,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":383.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":379.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":395.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":376.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":364.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":356.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":372.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$465.00

Average Price Target$430.32

Lowest Price Target$390.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lee Hambright

Bernstein

$465

Buy

27.82%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI) and Stryker (NYSE: SYK)

Matt Miksic

Barclays

$453→$462

Buy

27.00%

Upside

Reiterated

01/09/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK) and 10x Genomics (NASDAQ: TXG)

David Roman

Goldman Sachs

$418→$399

Hold

9.68%

Upside

Reiterated

01/09/26

Stryker price target lowered to $399 from $418 at Goldman SachsStryker price target lowered to $399 from $418 at Goldman Sachs

Shagun Singh Chadha

RBC Capital

$435

Buy

19.58%

Upside

Reiterated

01/07/26

Stryker (SYK) Gets a Buy from RBC Capital

Jayson Bedford

Raymond James

$418

Buy

14.90%

Upside

Upgraded

01/06/26

Raymond James upgrades Stryker (SYK) to a Buy

Vijay Kumar

Evercore ISI

$405→$390

Buy

7.21%

Upside

Reiterated

01/05/26

Stryker price target lowered to $390 from $405 at Evercore ISIStryker price target lowered to $390 from $405 at Evercore ISI

David Turkaly

Citizens JMP

$440

Buy

20.95%

Upside

Upgraded

12/19/25

Stryker upgraded to Outperform from Market Perform at CitizensStryker upgraded to Outperform from Market Perform at Citizens

Richard Newitter

Truist Financial

$400→$392

Hold

7.76%

Upside

Reiterated

12/18/25

Stryker price target lowered to $392 from $400 at TruistStryker price target lowered to $392 from $400 at Truist

Caitlin Cronin

Canaccord Genuity

$351.69→$435

Buy

19.58%

Upside

Reiterated

12/16/25

Canaccord Genuity Keeps Their Buy Rating on Stryker (SYK)

Joanne Wuensch

Citi

$455→$420

Buy

15.45%

Upside

Reiterated

12/12/25

Stryker price target lowered to $420 from $455 at CitiStryker price target lowered to $420 from $455 at Citi

Robbie Marcus

J.P. Morgan

Buy

―

Reiterated

11/14/25

J.P. Morgan Reaffirms Their Buy Rating on Stryker (SYK)

Larry Biegelsen

Wells Fargo

$452→$456

Buy

25.35%

Upside

Reiterated

11/14/25

Wells Fargo Keeps Their Buy Rating on Stryker (SYK)

Michael Matson

Needham

$448

Buy

23.15%

Upside

Reiterated

11/14/25

Stryker's Strategic Growth Plans and Market Leadership Reinforce Buy Rating

Rick Wise

Stifel Nicolaus

$440

Buy

20.95%

Upside

Reiterated

11/14/25

Stifel Nicolaus Reaffirms Their Buy Rating on Stryker (SYK)

Matthew O'Brien

Piper Sandler

$420

Buy

15.45%

Upside

Reiterated

11/14/25

Piper Sandler Reaffirms Their Buy Rating on Stryker (SYK)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lee Hambright

Bernstein

$465

Buy

27.82%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (NASDAQ: TLSI) and Stryker (NYSE: SYK)

Matt Miksic

Barclays

$453→$462

Buy

27.00%

Upside

Reiterated

01/09/26

Analysts Offer Insights on Healthcare Companies: Stryker (NYSE: SYK) and 10x Genomics (NASDAQ: TXG)

David Roman

Goldman Sachs

$418→$399

Hold

9.68%

Upside

Reiterated

01/09/26

Stryker price target lowered to $399 from $418 at Goldman SachsStryker price target lowered to $399 from $418 at Goldman Sachs

Shagun Singh Chadha

RBC Capital

$435

Buy

19.58%

Upside

Reiterated

01/07/26

Stryker (SYK) Gets a Buy from RBC Capital

Jayson Bedford

Raymond James

$418

Buy

14.90%

Upside

Upgraded

01/06/26

Raymond James upgrades Stryker (SYK) to a Buy

Vijay Kumar

Evercore ISI

$405→$390

Buy

7.21%

Upside

Reiterated

01/05/26

Stryker price target lowered to $390 from $405 at Evercore ISIStryker price target lowered to $390 from $405 at Evercore ISI

David Turkaly

Citizens JMP

$440

Buy

20.95%

Upside

Upgraded

12/19/25

Stryker upgraded to Outperform from Market Perform at CitizensStryker upgraded to Outperform from Market Perform at Citizens

Richard Newitter

Truist Financial

$400→$392

Hold

7.76%

Upside

Reiterated

12/18/25

Stryker price target lowered to $392 from $400 at TruistStryker price target lowered to $392 from $400 at Truist

Caitlin Cronin

Canaccord Genuity

$351.69→$435

Buy

19.58%

Upside

Reiterated

12/16/25

Canaccord Genuity Keeps Their Buy Rating on Stryker (SYK)

Joanne Wuensch

Citi

$455→$420

Buy

15.45%

Upside

Reiterated

12/12/25

Stryker price target lowered to $420 from $455 at CitiStryker price target lowered to $420 from $455 at Citi

Robbie Marcus

J.P. Morgan

Buy

―

Reiterated

11/14/25

J.P. Morgan Reaffirms Their Buy Rating on Stryker (SYK)

Larry Biegelsen

Wells Fargo

$452→$456

Buy

25.35%

Upside

Reiterated

11/14/25

Wells Fargo Keeps Their Buy Rating on Stryker (SYK)

Michael Matson

Needham

$448

Buy

23.15%

Upside

Reiterated

11/14/25

Stryker's Strategic Growth Plans and Market Leadership Reinforce Buy Rating

Rick Wise

Stifel Nicolaus

$440

Buy

20.95%

Upside

Reiterated

11/14/25

Stifel Nicolaus Reaffirms Their Buy Rating on Stryker (SYK)

Matthew O'Brien

Piper Sandler

$420

Buy

15.45%

Upside

Reiterated

11/14/25

Piper Sandler Reaffirms Their Buy Rating on Stryker (SYK)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stryker

3 Months

xxx

Success Rate

12/17 ratings generated profit

Average Return

+4.68%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +4.68% per trade.

1 Year

Larry BiegelsenWells Fargo

Success Rate

18/24 ratings generated profit

Average Return

+11.85%

reiterated a buy rating 2 months ago

Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +11.85% per trade.

2 Years

xxx

Success Rate

26/28 ratings generated profit

Average Return

+21.88%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +21.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SYK Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SYK has received 25 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. SYK average Analyst price target in the past 3 months is 430.32.

Each month's total comprises the sum of three months' worth of ratings.

SYK Financial Forecast

SYK Earnings Forecast

Next quarter’s earnings estimate for SYK is $4.39 with a range of $4.34 to $4.43. The previous quarter’s EPS was $3.19. SYK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SYK has Performed in-line its overall industry.

SYK Sales Forecast

Next quarter’s sales forecast for SYK is $7.12B with a range of $6.97B to $7.24B. The previous quarter’s sales results were $6.06B. SYK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SYK has Performed in-line its overall industry.

SYK Stock Forecast FAQ

What is SYK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stryker Corporation’s 12-month average price target is 430.32.

What is SYK’s upside potential, based on the analysts’ average price target?

Stryker Corporation has 18.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SYK a Buy, Sell or Hold?

Stryker Corporation has a consensus rating of Strong Buy which is based on 17 buy ratings, 3 hold ratings and 0 sell ratings.

What is Stryker Corporation’s price target?

The average price target for Stryker Corporation is 430.32. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $465.00 ,the lowest forecast is $390.00. The average price target represents 18.29% Increase from the current price of $363.78.

What do analysts say about Stryker Corporation?

Stryker Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of SYK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Stryker (SYK) Stock Forecast & Price Target

SYK Analyst Ratings

SYK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stryker

SYK Analyst Recommendation Trends

SYK Financial Forecast

SYK Earnings Forecast

SYK Sales Forecast

SYK Stock Forecast FAQ

Detailed List of Analyst Forecasts